Newsroom
Filter
EULAR Congress 2025
EULAR Congress 2025
Read More
AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
Read MoreAbolerIS Pharma Announces Formation of Scientific Advisory Board
AbolerIS Pharma Announces Formation of Scientific Advisory Board
Read More
ACR Convergence 2024
ACR Convergence 2024
Read MoreEULAR Congress 2024
EULAR Congress 2024
Read More
AbolerIS is 4 years old!
AbolerIS is 4 years old!
Read More
Joint Belgian-Dutch Immunology Meeting 2023
Joint Belgian-Dutch Immunology Meeting 2023
Read More
European Lifestars Awards
European Lifestars Awards
Read More
BIO-EUROPE
BIO-EUROPE
Read More
AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases
AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases
Read More
AbolerIS Pharma is one of the laureates of the REACT-EU program 2022
AbolerIS Pharma is one of the laureates of the REACT-EU program 2022
Read More
GO Immuno Meeting 2023
GO Immuno Meeting 2023
Read More
Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome
Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome
Read MoreAIRE deficiency, from preclinical models to human APECED disease.
AIRE deficiency, from preclinical models to human APECED disease.
Read MoreSuper-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications
Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications
Read MoreTransient antibody targeting of CD45RC inhibits the development of graft-versus-host disease
Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease
Read MoreHuman CD8+ Tregs expressing a MHC-specific chimeric antigen receptor display enhanced suppression of human skin rejection and GVHD in NSG mice
Human CD8+ Tregs expressing a MHC-specific chimeric antigen receptor display enhanced suppression of human skin rejection and GVHD in NSG mice
Read MoreImmunophenotype of a rat model of Duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment
Immunophenotype of a rat model of Duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment
Read MoreAdvances on CD8+ Tregs and their potential in transplantation
Advances on CD8+ Tregs and their potential in transplantation
Read MoreEx vivo expanded human non-cytotoxic CD8+CD45RClow/− Tregs efficiently delay skin graft rejection and GVHD in humanized mice
Ex vivo expanded human non-cytotoxic CD8+CD45RClow/− Tregs efficiently delay skin graft rejection and GVHD in humanized mice
Read MoreTransient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.
Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.
Read MoreDonor MHC-derived peptide recognized by TCR biased-CD8+ Tregs suppresses organ rejection
Donor MHC-derived peptide recognized by TCR biased-CD8+ Tregs suppresses organ rejection
Read MoreMechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance
Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance
Read MoreAnti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients
Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients
Read MoreInhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade
Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade
Read MoreCD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFNgamma and indoleamine 2,3 dioxygenase